Prev: Iron and Dialysis Death
Next: Creatinine % increased in blood.
From: ironjustice on 19 Aug 2007 12:05
MORE .. chemical .. bloodletting.

Transplantation Proceedings
Volume 37, Issue 3, April 2005, Pages 1586-1588

doi:10.1016/j.transproceed.2004.09.014
Copyright © 2005 Elsevier Inc. All rights reserved.
Valsartan-Induced Hematocrit Changes in Renal Transplant Patients

C.A. Flores, , L.G. Ardiles, C.A. Aros, C.C. Muñoz, H.O. Schneider,
J.A. Ramı́rez, V. Jerez, M.G. Valderrama and S.A. Mezzano
Unidad de Nefrologı́a; Hospital Regional de Valdivia, Valdivia, Chile

Available online 29 April 2005.

Abstract

Background

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II
receptor type 1 blockers (ARB) are frequently prescribed for renal
transplant patients. The main reasons for their use are that their
antihypertensive and antifibrogenic effects may prevent chronic renal
allograft dysfunction, potentially improving transplant survival.
Furthermore, ACE and ARB have been used to reduce the hematocrit in
patients with posttransplant erythrocytosis. We evaluated the effects
of the ARB valsartan on the evolution of hematocrit in stable renal
transplant patients treated with cyclosporine (CsA), azathioprine
(Aza), and prednisone.

Patients and methods

Twenty-six stable renal transplant patients treated with valsartan 80
mg/d orally were followed for 6 months. Evaluations were performed
prior to as well as at 3 and 6 months following the initiation of
valsartan.

Results

The hematocrit levels decreased significantly at 3 months (46.1 ± 7.3
vs 39.9 ± 5.8 ; P < .0001) in patients with a normal hematocrit,
namely a level over 38%, with no further reduction at 6 months. In
recipients with an hematocrit less than 38%, there was no significant
reduction, either at 3 or 6 months follow-up. Valsartan was well
tolerated without significant side effects.

Conclusion

We postulate that inhibition of the proerythropoietic effects of
angiotensin II and/or the reduction in hypoxia within the renal
tubulointerstitium as well as the vasodilator effects on the efferent
arterioles, represent possible mechanisms for the reduction and
stabilization of the hematocrit in stable renal transplant patients.


This study was supported by grants DID-UACH S-200275 and Fondecyt
(Chile) 1040163 and 1030263
Address reprint requests to Claudio Flores, MD; Unidad de Nefrologı́a,
Hospital Regional de Valdivia, Bueras 1003, Valdivia, Chile


Transplantation Proceedings
Volume 37, Issue 3, April 2005, Pages 1586-1588


Who loves ya.
Tom


Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com


Man Is A Herbivore!
http://tinyurl.com/a3cc3


DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk

 | 
Pages: 1
Prev: Iron and Dialysis Death
Next: Creatinine % increased in blood.